An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti‐Angiogenic Agents for Therapy: A Case Report

ABSTRACT Background Although the presence of Kirsten murine sarcoma virus (KRAS) mutations predicts a failure of non‐small cell carcinoma (NSCLC) patients to benefit from epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) therapy it may be more sensitive to programmed combinatio...

書誌詳細
出版年:	Cancer Reports
主要な著者:	Li Wang, Jiaqi Wu, Ping Shao, Wuping Bao, Lin Mao, Zhendong Pan, Aihua Bao, Min Zhang, Zhenghua Wu, Guorong Fan
フォーマット:	論文
言語:	英語
出版事項:	Wiley 2025-06-01
主題:	anti‐angiogenic agents camrelizumab case report KRAS mutations lung adenocarcinoma
オンライン･アクセス:	https://doi.org/10.1002/cnr2.70186

類似資料

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
著者:: Veronica Aran, 等
出版事項: (2021-09-01)

The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma
著者:: Shangshang Ma, 等
出版事項: (2024-12-01)

Efficacy of continuing anti-angiogenic agents in the second-line treatment for metastatic colon cancer depending on the KRAS mutation status: a meta-analysis
著者:: M. Yu. Fedyanin, 等
出版事項: (2018-07-01)

Successful treatment of recurrent sarcomatous choledochal carcinoma with camrelizumab and apatinib
著者:: Shilei Li
出版事項: (2023-11-01)

Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report
著者:: Xuhua Huang, 等
出版事項: (2024-12-01)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
著者:: Prashanth Ashok Kumar, 等
出版事項: (2023-06-01)

Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery
著者:: Dong Woog Yoon, 等
出版事項: (2025-01-01)

A case report of high-grade fetal lung adenocarcinoma with KRAS mutation
著者:: Wang Jiaqi, 等
出版事項: (2024-01-01)

SMARCA4 mutations in KRAS‐mutant lung adenocarcinoma: a multi‐cohort analysis
著者:: Liang Liu, 等
出版事項: (2021-02-01)

Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways
著者:: Hnin Ei Ei Khine, 等
出版事項: (2025-04-01)

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
著者:: Albert Grinshpun, 等
出版事項: (2019-01-01)

Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients
著者:: In Seok Yang, 等
出版事項: (2018-02-01)

Camrelizumab-induced immune-related toxic epidermal necrolysis in lung adenocarcinoma: a case report and literature review
著者:: Man Sun, 等
出版事項: (2025-01-01)

Incidence Of Kras Mutations In Colon Adenocarcinomas And Its Association With Lymph Node Metastases
著者:: Gökhan Varlı, 等
出版事項: (2020-06-01)

ZNF24 regulates the progression of KRAS mutant lung adenocarcinoma by promoting SLC7A5 translation
著者:: Daqi Jia, 等
出版事項: (2022-11-01)

Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma
著者:: Yuqiong Wang, 等
出版事項: (2021-05-01)

The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis
著者:: Rui Zhao, 等
出版事項: (2024-11-01)

Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study
著者:: Fan Yang, 等
出版事項: (2024-01-01)

KRAS mutation promotes immune escape of lung adenocarcinoma via ZNF24/SLC7A5/PD-L1 axis
著者:: Leilei Li, 等
出版事項: (2025-09-01)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
著者:: Berardino Prencipe, 等
出版事項: (2023-06-01)

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
著者:: Zhou WJ, 等
出版事項: (2024-12-01)

Case report: A case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: A new immune-related adverse event
著者:: Ping-Shang Wu, 等
出版事項: (2022-08-01)

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC
著者:: Alessandro Tubita, 等
出版事項: (2025-09-01)

Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
著者:: Kohei Okada, 等
出版事項: (2023-01-01)

MVK, induced by Kras, represses cGAS-Sting signalling in lung adenocarcinoma
著者:: Changsheng Zhou, 等
出版事項: (2025-01-01)

A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in KRAS‐mutant invasive non‐mucinous adenocarcinoma
著者:: Kaiwen Chi, 等
出版事項: (2022-04-01)

Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma
著者:: Gaku Shimane, 等
出版事項: (2024-09-01)

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
著者:: Jan Rehkaemper, 等
出版事項: (2020-06-01)

Novel insights into the RTK-dependent metastatic phenotype of KRAS-mutant lung adenocarcinoma
著者:: Mariana Cooke
出版事項: (2021-11-01)

Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors
著者:: Xile Zhou, 等
出版事項: (2023-04-01)

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
著者:: Yanfei Liu, 等
出版事項: (2024-03-01)

KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma
著者:: Mahmoud Yousef, 等
出版事項: (2025-04-01)

Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma
著者:: Prasanna Srinivasan Ramalingam, 等
出版事項: (2025-07-01)

Elevated KRAS protein level is associated with better survival in pancreatic cancer
著者:: S. M. Stålberg, 等
出版事項: (2025-07-01)

Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer
著者:: Nawaz Khan, 等
出版事項: (2025-07-01)

An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma
著者:: Yunqian Chu, 等
出版事項: (2024-08-01)

Clinical Significance of the KRAS Mutation
著者:: Sead Beganovic
出版事項: (2010-10-01)

Pulmonary mucinous adenocarcinoma: An overview of pathophysiology and advancements in treatment
著者:: Lihui Ge, 等
出版事項: (2024-05-01)

Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy
著者:: İsa Taş, 等
出版事項: (2025-04-01)

Resistance to KRAS inhibition in advanced non-small cell lung cancer
著者:: Katherina Bernadette Sreter, 等
出版事項: (2024-05-01)